After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...
Amgen’s Lumakras and AstraZeneca’s Calquence ... The drug is a significant sales (PDF) driver within the company’s oncology portfolio, bringing in $2.3 billion over the first nine months ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback